News
ETON
23.58
-2.40%
-0.58
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Eton Pharmaceuticals (ETON) and Ligand Pharma (LGND)
TipRanks · 2d ago
Eton Starts Pilot Trial of ET-700 for Wilson Disease
TipRanks · 2d ago
Eton Pharmaceuticals says first patient dosed in study of ET-700
TipRanks · 2d ago
Eton Pharma Announces First Patient Dosed In Pilot Clinical Study Assessing Efficacy Of ET-700 For Treatment Of Wilson Disease; Topline Study Results Expected In H2 2026
Benzinga · 2d ago
Eton Pharmaceuticals doses first patient in ET-700 Wilson disease pilot trial
PUBT · 2d ago
ETON PHARMACEUTICALS INC - DOSES FIRST PATIENT IN PILOT STUDY OF ET-700 FOR WILSON DISEASE
Reuters · 2d ago
Weekly Report: what happened at ETON last week (0420-0424)?
Weekly Report · 2d ago
Weekly Report: what happened at ETON last week (0413-0417)?
Weekly Report · 04/20 09:05
Eton Pharma drops after CFO succession plan
Seeking Alpha · 04/16 17:03
Analysts Offer Insights on Healthcare Companies: Eton Pharmaceuticals (ETON), BioNTech SE (BNTX) and CareDx (CDNA)
TipRanks · 04/16 14:20
Eton Pharmaceuticals Names Judith Matthews CFO, Effective June 1
NASDAQ · 04/16 12:02
Eton Pharmaceuticals Announces New Chief Financial Officer Appointment
TipRanks · 04/16 11:32
Eton Pharmaceuticals appoints Judith Matthews as CFO
TipRanks · 04/16 11:31
Eton Pharmaceuticals Names Judith Matthews Chief Financial Officer
Dow Jones · 04/16 11:18
*Eton Pharmaceuticals Announces Appointment of Judith Matthews as Exec VP, Chief Financial Officer
Dow Jones · 04/16 10:51
Eton Pharma names Judy Matthews CFO, succeeding James Gruber
PUBT · 04/16 10:50
ETON PHARMACEUTICALS ANNOUNCES CFO SUCCESSION PLAN
Reuters · 04/16 10:50
ETON PHARMACEUTICALS INC - JAMES GRUBER TO STEP DOWN AS CFO EFFECTIVE MAY 31, 2026
Reuters · 04/16 10:50
Press Release: Eton Pharmaceuticals Announces CFO Succession Plan
Dow Jones · 04/16 10:50
Eton Pharmaceuticals Announces CFO Succession Plan
Barchart · 04/16 05:50
More
Webull provides a variety of real-time ETON stock news. You can receive the latest news about Eton Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About ETON
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.